AI-Powered MRI Enhancement Solution, SwiftMR™, Approved for Use in Canada
SwiftMR™ approved for use
Operating under the laws of the Food and Drugs Act, the Medical Devices Regulations, and supporting guidance documents, Health Canada regulates the sale and importation of medical devices such as MRI scanners. SwiftMR™ has been approved by Health Canada. Since SwiftMR™ is a vendor-neutral application, the MRI scan reconstruction technology can be used in any MRI scanner, regardless of make, model, and field strength.
"Securing Health Canada approval marks a significant milestone for AIRS Medical," remarked CEO
A step forward for healthcare in
Through the following benefits, SwiftMR™ helps healthcare providers deliver high quality care:
- Quicker scans: SwiftMR™ reduces scan times by up to 50%*, allowing imaging centers to provide timely care to more patients.
- Greater image quality: Deep learning algorithms reconstruct images to make them more detailed, aiding radiologists in detecting and diagnosing medical conditions.
- Cost efficiency: Rather than investing in costly upgrades or a new scanner, radiology centers can extend the life and improve the quality of their existing device.
- Broad application: Approved for use in all body parts and for all patients, SwiftMR™ seamlessly integrates with both state-of-the-art and legacy machines, regardless of the manufacturer.
The SwiftMR™ difference
Now available in over 50 countries and found in more than 400 institutions, SwiftMR™ is helping to increase patient access to diagnostic imaging services worldwide.
To learn more about AIRS Medical and SwiftMR™, visit https://airsmed.com/en.
AIRS Medical
Director of Global Marketing
[email protected]
*For investigational purposes in countries outside of
View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-powered-mri-enhancement-solution-swiftmr-approved-for-use-in-canada-302209058.html
SOURCE AIRS Medical
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
- TIER IV joins Open Invention Network 2.0 to drive the expansion of the open-source ecosystem for autonomous driving through a patent strategy
- Bavarian Nordic Upgrades its Full-Year 2026 Financial Guidance
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share